Background: Aesthetic medicine has traditionally focused on patient-related psychological vulnerabilities, particularly Body Dysmorphic Disorder (BDD). However, significantly less attention has been given to perceptual and cognitive changes occurring in aesthetic practitioners themselves. Purpose: This article introduces and conceptualizes Professional Aesthetic Drift (PAD), defined as a progressive shift in clinicians’ aesthetic perception, judgment, and treatment thresholds resulting from chronic exposure to altered beauty standards, procedural repetition, and algorithm-driven social media environments. Methods: Drawing on evidence from visual neuroscience, psychology, and sociocultural research, this paper develops a theoretical framework explaining how prolonged exposure to modified facial morphologies may induce perceptual adaptation and internal recalibration of aesthetic norms. Results: We argue that aesthetic practitioners, due to their professional environment, are not only healthcare providers but also cultural agents and generators of contemporary beauty standards. PAD is conceptualized not as a psychopathology, but as an occupational perceptual bias comparable to expertise-related adaptations observed in other high-exposure professions. Conclusion: Preventive strategies, clinical indicators and future research directions are proposed to investigate and mitigate this phenomenon. Recognizing PAD may promote more reflective, ethical, and perceptually balanced aesthetic practice. Plain Language Summary: Professional Aesthetic Drift (PAD) describes a progressive perceptual and clinical shift in aesthetic practitioners.PAD is driven by visual adaptation, procedural repetition, and social media reinforcement.The phenomenon is conceptualized as an occupational perceptual bias, not a psychopathology.PAD may contribute to normalization of extreme aesthetic outcomes. Awareness and perceptual recalibration strategies may improve ethical and clinical practice.

Background: Hyaluronic acid (HA) filler-based aesthetic improvement of the lips is popular with patients. However, it is complicated by great diversity in individual desires and underlying morphology. Many injection techniques have been published, but there is a need to integrate these within a methodological framework for codified lip analysis and treatment planning. The LA VISION Method provides such a framework. This paper describes the methodology, explains the coding language, and illustrates its clinical application. Methods: The LA VISION Method is composed of three consecutive and interdependent phases: (1) MAP, which establishes the morpho-geometric structure of the lips through anthropometric lines and defined topographic mapping, using a novel coding system; (2) ASSESS, which collects and analyzes patient-specific information, such as aesthetic desires, detailed lip morphology, and facial proportions, to define their current and ideal lip structure; and (3) PLAN, which translates the assessment into a tailored logic-based injection strategy to convert lip structure towards the defined ideal and individual shape. Results: An initial cohort of 400 patients (mean age: 41.0 years; 53.2% female) was treated using a mean filler volume of 1.00 ± 0.01 mL (first session). Adverse events were typically localized and mild in severity; no major complications were observed. Patient-reported outcomes were positive. Conclusions: The LA VISION Method provides a systematic, logical, clinically usable approach with a reproducible decision logic for lip analysis and injection planning using HA fillers. It also creates a common language for clinician training, documentation, communication with peers and patients, and future digital integration. Further studies are warranted. Level of Evidence IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .

Facial neuromodulation with botulinum toxin has traditionally been approached from the perspective of wrinkle correction. However, facial expressions primarily arise from coordinated muscular interactions that convey both positive and negative emotional valence. A conceptual framework focused on muscular equilibrium rather than wrinkle severity may therefore offer a more comprehensive, reproducible, and clinically meaningful approach. In this article, we propose the Index of Muscular Equilibrium (IME) Framework, a conceptual model for aesthetic neuromodulation that integrates functional muscle mapping, validated severity scales, and a composite IME score to support personalized treatment planning and outcome assessment. The framework is derived from a narrative review of PubMed-indexed literature on facial muscle activity, emotional expression, and validated clinical assessment tools. It combines a Valence Map to classify positive- and negative-valence muscle groups, a standardized evaluation of static and dynamic hypertonus, a conceptual Plan Score to guide selective neuromodulation, and a feedback-based longitudinal workflow (the IME Loop). Together, these components enable structured assessment of muscular imbalance, integration of established wrinkle severity scales, and translation into individualized, function-oriented treatment strategies, with intended benefits including improved objectivity, reproducibility, and patient communication. By reframing treatment success from the duration of muscle blockade to the duration of expressive harmony, the IME Framework introduces testable constructs for future validation and offers a functional perspective on facial neuromodulation aligned with contemporary affective science.

Botulinum neurotoxin type A (BoNT-A) is used across coexisting craniocervical conditions, and therapeutic response is often overinterpreted as evidence of a shared generator. The bruxism literature shows why. Across six controlled studies with event-level outcome measurement, reported effects on event frequency track not dose or injection field but whether the rule used to detect an event could follow the amplitude the toxin had just reduced; none yet combines a placebo arm with an amplitude-independent event definition. This targeted critical narrative review interprets representative evidence mechanistically rather than assessing efficacy. It examines chronic migraine, tension-type headache, myogenous temporomandibular disorders, and bruxism, with somatosensory tinnitus as a cross-modal boundary case. Efficacy is protocol-specific in chronic migraine and uncertain elsewhere. Tracing studies locate somatosensory routes to the cochlear nucleus in the spinal trigeminal and dorsal column nuclei; a direct mesencephalic-trigeminal-to-cochlear projection has not been demonstrated in the tracing literature reviewed, so somatic–auditory plausibility does not establish the masticatory proprioceptive route invoked by muscle-targeted rationales. Because BoNT-A affects motor output, peripheral nociceptive signaling, and muscle spindle input—the last of these probably differing in availability across injection fields—we frame it as a site-dependent, multi-output perturbation. That pharmacology is established; what is offered here is the inferential framing and the anatomical constraint following from it.

Excessive gingival display (EGD) is most commonly attributed to vertical upper lip elevation, short lip length, or dentoalveolar disproportion. However, some patients exhibit gingival or mucosal visibility during smiling despite minimal vertical upper lip displacement, suggesting the presence of alternative dynamic patterns. This exploratory case series examined an inversion-dominant smile presentation and its documented modulation in association with conservative intraoral chemodenervation directed toward the marginal region of the orbicularis oris. Ninety-four patients with dynamic inversion during smiling were assessed using a qualitative rating aid (Armenti Inversion Scale, AIS) and a quantitative composite proportional measure of vermilion loss (ΔLv%). All patients received low-dose intraoral Onabotulinum toxin A (4–6 U) as part of routine aesthetic care. At Day 15 follow-up, a shift toward lower inversion grades was observed across the cohort, with a large proportion of patients showing minimal residual inversion. Quantitative ΔLv% values showed proportional changes that were directionally consistent with shifts in AIS grade. The functional alterations were mild, transient, and self-resolving. Preliminary inter-rater agreement for AIS and measurement repeatability for ΔLv% suggested acceptable internal consistency for exploratory reporting tools. These findings suggest that inward vermilion inversion may represent a potentially distinct dynamic contributor to gingival or mucosal exposure in selected individuals, and that conservative marginal chemodenervation was associated with transient modulation of this pattern with generally preserved oral competence. AIS and ΔLv% are preliminary documentation tools. Further studies incorporating objective neuromuscular assessment, three-dimensional imaging, and comparative designs are required to refine phenotypic characterization.